ALIBETEZIN

COMPOSITION
Dapagliflozin…………………………………..10mg
INDICATIONS

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
  • Chronic Kidney Disease: Indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
  • Heart Failure: indicated to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent heart failure visit in adults with HF.

PACKAGING:

  • 7 tablets/blister, 2 blisters/box.
  • 7 tablets/blister, 50 blisters/box.

Reg No: 08 L 1177/24
Download ALIBETEZIN Drug Registration Certificate

Brand name: ALIBETEZIN


Composition:
Each tablet contains:
Dapagliflozin……………………..10mg


Indications:

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
  • Chronic Kidney Disease: Indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
  • Heart Failure: indicated to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent heart failure visit in adults with HF.

Dosage:

  • Blood glucose control: Oral administration. It is recommended to take it in the morning, with a starting dose of 5mg each time, once a day. According to blood sugar levels, the dosage can be increased to 10mg per dose, once a day.
  • Heart failure or: Take 10mg orally once a day.
  • Chronic kidney disease: 10mg orally once a day.

Contraindications:

  • History of serious hypersensitivity reaction to the product.
  • Contraindicated in dialysis patients.

Warnings:

  • This product is not applicable to type I diabetes or type I diabetes ketoacidosis.
  • Dapagliflozin can cause osmotic diuresis, which may lead to reduced blood volume.
  • In combination with sulfonylureas or insulin may cause hypoglycemia.
  • Genital fungal infection.
  • Pay attention to perineal necrotizing fasciitis.
  • Pregnant and lactating women should use with caution.
  • Use with caution for children.

Adverse Effects:
Renal impairment, female genital fungal infections, nasopharyngitis, and urinary tract infections.


Dosage form: Yellow tablets.


Expiry date: 24 months after date of manufacture.


Packaging:

  • 7 tablets/blister, 2 blisters/box.
  • 7 tablets/blister, 50 blisters/box.

Storage:

  • Protected from light, sealed, and stored at 20℃- 25℃.
  • Keep out of reach of children.

DISCLAIMER

The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.

For your safety:

Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.